Acceleron to Webcast Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
Acceleron Pharma (Nasdaq:XLRN) will host a webcast and conference call on February 25, 2021, at 5:00 p.m. EST to discuss its Q4 and full year 2020 financial results. The event will be accessible via their website under 'Events & Presentations'. The company focuses on therapeutics for serious rare diseases, with developments in pulmonary treatments, including sotatercept for pulmonary arterial hypertension (PAH) and REBLOZYL for anemia in blood disorders through a collaboration with Bristol Myers Squibb.
- Positive topline results of the PULSAR Phase 2 trial for sotatercept.
- Plans for multiple Phase 3 trials for sotatercept to establish it as backbone therapy for PAH.
- None.
Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, February 25, 2021 at 5:00 p.m. EST to discuss its fourth quarter and full year 2020 financial results.
The webcast will be accessible under "Events & Presentations" in the Investors & Media page of the Company’s website at acceleronpharma.com. To participate in the conference call, please dial 833-494-1483 (domestic) or 236-714-2620 (international) and reference code #4282162.
An archived version of the webcast will be available for replay on the Company’s website for approximately one year.
About Acceleron
Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron’s leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.
Acceleron focuses its research, development, and commercialization efforts in pulmonary and hematologic diseases. In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension (PAH), having reported positive topline results of the PULSAR Phase 2 trial. The Company is currently planning multiple Phase 3 trials with the potential to support its long-term vision of establishing sotatercept as a backbone therapy for patients with PAH at all stages of the disease. Acceleron is also investigating the potential of its early-stage pulmonary candidate, ACE-1334, which it plans to advance into a Phase 1b/2 trial in systemic sclerosis-associated interstitial lung disease (SSc-ILD) this year.
In hematology, REBLOZYL® (luspatercept-aamt) is the first and only erythroid maturation agent approved in the United States, Europe, and Canada for the treatment of anemia in certain blood disorders. REBLOZYL is part of a global collaboration partnership with Bristol Myers Squibb. The Companies co-promote REBLOZYL in the United States and are also developing luspatercept for the treatment of anemia in patient populations of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis.
For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210217005091/en/
FAQ
What are the details of the upcoming conference call for Acceleron Pharma (XLRN)?
What is Acceleron Pharma's focus in drug development?
What recent trial results did Acceleron Pharma announce regarding sotatercept?
How is REBLOZYL related to Acceleron Pharma (XLRN)?
